• J J Brady, R K Crowley, B F Murray, M T Kilbane, M O'Keane, and M J McKenna.
• Metabolism Laboratory, St. Vincent's University Hospital, Dublin, Ireland, jbrady@mater.ie.
• Ir J Med Sci. 2014 Mar 1; 183 (1): 47-52.

BackgroundTartrate-resistant acid phosphatase isoform 5b (TRACP5b) is a serum bone resorption marker. Our aim was to investigate its utility in monitoring metabolic bone disease.MethodsSerum TRACP5b, C-terminal cross-linking telopeptide of type I collagen, urine N-terminal cross-linking telopeptide of type I collagen and free deoxypyridinoline were measured pre- and post-treatment with a parathyroid hormone analogue [PTH (1-34)] (n = 14) or a bisphosphonate (N-BP) (n = 8). TRACP5b, bone alkaline phosphatase (bone ALP), 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in 100 osteoporosis patients on prolonged bisphosphonate therapy.ResultsChanges in TRACP5b were smaller in magnitude but mimicked those of other bone resorption markers. Absolute changes in TRACP5b and the other resorption markers correlated significantly (p < 0.001). In patients on long-term bisphosphonates, TRACP5b and bone ALP levels were not suppressed. Vitamin D status was consistent with the level of supplementation.ConclusionTRACP5b has limited utility as a single marker of metabolic bone disease treatment.

44 keywords...

hide…